MESO

News Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today - The Motley Fool Australia

14d ago

News Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

14d ago

News Mesoblast reports Q1 results

33d ago

News Mesoblast gains on licensing deal for CAR technology platform

48d ago

SEC filing MESO Acquires CAR-MSC Platform, $200M Deal, Mayo Clinic License, Targets Lupus Nephritis, IBD

48d ago

Insider trade Purchase by George Gregory

50d ago

Insider trade Purchase by George Gregory

52d ago

News Mesoblast gains as FDA clears study to test Ryoncil in Duchenne

55d ago

SEC filing MESO R&D Day Highlights $100M Ryoncil Revenue, CLBP Phase 3 Enrollment, CAR Platform Acquisition

55d ago

SEC filing MESO Reports $30.3M Ryoncil Net Sales, $100M Revenue Milestone, FDA‑Approved MSC Therapy, R&D Day April 8

55d ago

SEC filing MESO Reports $10.2M Q1 Revenue, $0.02 EPS, +15% YoY, Announces FDA IND Clearance for Ryoncil® in DMD, 76-Patient Registrational Trial, Partners PPMD

55d ago

News Mesoblast drops after Ryoncil sales data for March quarter

56d ago

News Mesoblast misses H1 estimates

95d ago

SEC filing MESO Reports $30M Ryoncil Revenue, +60% QoQ, $125M Credit Line

124d ago

SEC filing MESO: Ryoncil® 84% Survival in Pediatric SR-aGvHD, 45+ Centers Onboarded, >260M Lives Covered, Adult Trial Starting

124d ago

News FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

134d ago

News Mesoblast rises as Ryoncil sales climb 60% in December quarter

143d ago

News Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

153d ago

News Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

153d ago

News Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

153d ago

Scanner Unusual volume (z=2.9)

165d ago